# Illumina, Inc.  Share Price Target ‘$152.81’, now 4.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/illumina-inc.share-price-target-152.81-now-4.6-upside-potential/4121143470
- Published: 2024-02-20T14:28:08+00:00
- Author: Charlotte Edwards

**Illumina, Inc.** with ticker code (ILMN) have now 21 confirmed analysts covering
the stock with the consensus suggesting a rating of ‘buy’. The range between the
high target price and low target price is between $258.00 and $85.00 and has a mean
share price target at $152.81. (at the time of writing). Now with the previous closing
price of $146.07 this would indicate that there is a potential upside of 4.6%. Also
worth taking note is the 50 day moving average now sits at $136.45 and the 200 day
moving average is $154.77. The company has a market capitalization of 22.79B. The
stock price for the company is currently is currently $143.41 USD

 The potential market cap would be $23,839,333,163 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.51 and
a -0.53% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic
and genomic analysis. The Company operates through two segments: Core Illumina and
GRAIL. Its Core Illumina segment offers products and services that serve customers
in the research, clinical and applied markets, and enable the adoption of a variety
of genomic solutions. Its GRAIL segment is a healthcare company focused on early
detection of multiple cancers. Its portfolio of integrated sequencing and microarray
systems, consumables, and analysis tools is designed to accelerate and simplify 
genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing
instruments, allowing customers to manage their biological sample and sequencing
runs, process and analyze the raw genomic data, and derive results. Its BeadArray
technology combines microscopic beads and a substrate in a proprietary manufacturing
process to produce arrays that can perform various assays simultaneously.

Share on:
